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The clinical data from abiraterone acetate and MDV-3100 confirm continued androgen receptor (AR) addic-
tion in a significant proportion of castration-resistant prostate cancers (CRPC). However, patients nearly
invariably progress with a rise in prostate-specific antigen, suggesting resumption of transcription of
hormone-regulated genes. If CRPC remains addicted to steroid receptor signaling, including, but not exclu-
sive, to AR, how does reactivation occur? Or if cancers lose this addiction, do they remain driven by the same
oncogenic mechanisms? The future development of therapeutics for CRPC should be informed by an under-
standing of the mechanisms underlying disease progression following treatment with these novel agents.Cancer of the prostate is the commonest
cancer in men in western societies,
accounting for 11% of male cancer deaths
(Jemal et al., 2008). The proliferation and
survival of prostate cancer cells is critically
dependent on androgen stimulation (Hug-
gins and Hodges, 1972), with treatment of
incurable advanced prostate cancer being
primarily based on androgen deprivation
by castration, which is achieved chemi-
cally. Such treatment frequently results in
dramatic remission, but the disease invari-
ably relapses to what has historically been
referred to as ‘‘hormone-refractory’’ pros-
tate cancer. To explain this observation,
Isaacs and Coffey (1981) proposed that
both hormone-resistant and hormone-
sensitive prostate cancer cells coexist
and that androgen withdrawal results in
the natural selection of the androgen-
resistant component (Isaacs and Coffey,
1981). This general model is broadly
consistent with recent evidence showing
that the prostate cancer clonogenic stem
cell population lacks androgen receptor
(AR) (Collins et al., 2005). Evidence indi-
cates, however, that despite the potential
existence of ‘‘androgen-independent’’
clones, the growth of the majority of
cancer cells in many patients with cancers
recurring after castration remains depen-
dent on the AR signaling axis:
d Studies of isogenic prostate cancer
cell lines grown in androgen-de-
prived conditions report that pro-
gression invariably occurs following
an increase in expression of AR
mRNA (Chen et al., 2004).458 Cancer Cell 16, December 8, 2009 ª200d High expression of enzymes in-
volved in steroid synthesis (Stan-
brough et al., 2006) allows CRPC
to maintain high intratumoral an-
drogen levels despite ongoing
castration (Mohler et al., 2004).
These adaptive changes by CRPC
suggest that the bulk of tumor
remains dependent on ligand acti-
vation of the AR.
d Aberrations of the AR gene that
could allow AR signaling occur with
increasing frequency in multidrug-
resistant CRPC (Buchanan et al.,
2001).
d A rise in serum prostate-specific
antigen (PSA), which is at least partly
related to AR transcriptional activity,
occurs in the majority of CRPC
patients at progression.
d Nuclear AR expression persists in
prostate cancer metastases from
patients who progressed on multiple
hormonal therapies (Shah et al.,
2004).
d CRPC patients benefit from repeated
further manipulations with agents tar-
geting steroid receptor signaling.
Critically, clinical data from recent
phase I/II clinical trials of two oral
agents, abiraterone acetate and
MDV-3100, have reported a high
level of antitumor activity in CRPC
(Attardetal., 2009b;Tranetal., 2009).
These efforts by cancer to reactivate
AR signaling at progression suggest
continued addiction to AR signaling or
other processes that modulate transcrip-9 Elsevier Inc.tion of PSA and other hormone-regulated
genes. The appealing corollary of this
hypothesis would be that clinical castra-
tion resistance could develop via mecha-
nisms that allow reactivation of the same
downstream processes that drive ther-
apy-naive cancer. We propose that thera-
peutic strategies aimed at modulating
activation of AR targets are therefore
likely to induce responses in multidrug-
resistant prostate cancer.
Hormone-Driven Oncogenesis
The AR initiates the development and
maintains regeneration of the prostate
gland through regulation of genes
involved in protein synthesis, secretion,
apoptosis, and transcription. Despite this
prodifferentiation function, androgen-
regulated genes are overexpressed in
primary prostate cancer and CRPC
compared with benign prostate epithelia,
and downregulation of these genes is
associated with clinical responses to
androgen ablation therapy (Massie et al.,
2007). Tomlins et al. report that
40%–70% of prostate cancers have a
chromosomal rearrangement that results
in hormonal regulation of oncogenic ETS
gene expression (Tomlins et al., 2005).
This could explain one mechanism by
which activation of the AR becomes onco-
genic. Upregulation of genes, such as
PSA, associated with prostate cancer
could therefore be a ‘‘bystander’’ effect
of the AR transcriptional activity required
for prostate cancer progression. The
most common ETS gene rearrangement
results in fusion of the androgen-regulated
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2005). We have reported an AR-binding
site in the genomic proximity of TMPRSS2
and also of other less commonly occurring
androgen-regulated ETS fusion partners,
including SLC45A3 and ACSL3 (Attard
et al., 2008a). In addition to AR, other
steroid receptors could be involved in the
regulation of ETS fusion partners (Setlur
et al., 2008).
ETS gene fusions appear to precede the
development of metastases, as there is
significant concordance in ETS gene
status of all CRPC metastases and
therapy-naive prostate cancer (Attard
et al., 2009c; Mehra et al., 2008). However,
ERG remains overexpressed in end-stage
ERG-rearranged CRPC (Attard et al.,
2009c; Cai et al., 2009), and in fact, Tom-
lins et al. first confirmed the existence of
ETS gene fusions in CRPC metastases
obtained at autopsy that overexpressed
ERG or ETV1 (Tomlins et al., 2005). This
provides further evidence that CRPC
undergoes adaptations in order to main-
tain overexpression of hormone-regulated
ETS genes.
ETS gene rearrangements and other
genomic aberrations are not present in
stromal cells, but there is strong preclin-
ical evidence that stromal-epithelial inter-
actions play an important role in prostate
carcinogenesis (Cunha et al., 2002).
Growth factors produced by prostate
stromal cells can activate steroid receptor
signaling pathways, and the efficacy of
current hormonal therapies in targeting
such paracrine loops is unclear. Steroid
receptor-mediated transcriptional activity
is altered in malignant stroma (Cano
et al., 2007), and it therefore cannot be
assumed that ablation of stromal steroid
receptor signaling is necessarily thera-
peutic. Current xenograft models fail to
accurately mimic human tumor stromal
conditions, and a better understanding
of the stromal-epithelial interplay is de-
pendent on more clinically representative
preclinical models.
Abiraterone Acetate and MDV3100
Abiraterone acetate is a highly specific
inhibitor of CYP17 and results in signifi-
cant suppression of serum androgenic
steroids and estrogens (Attard et al.,
2008b). We and others have reported
declines in PSA by R50% and R90%,
with abiraterone acetate in 50%–60%
and 20%–30% of CRPC patients, respec-tively (Attard et al., 2009a). Importantly,
declines in PSA were associated with
radiological tumor regression, declines
in circulating tumor cell (CTC) count,
and symptomatic benefit (Attard et al.,
2009a). MDV-3100 is a potent AR antago-
nist that also induces tumor responses in
CRPC patients that have failed other
hormonal therapies (Tran et al., 2009).
This antitumor activity in heavily pre-
treated (standard antiandrogens, low-
dose steroids, estrogens, and docetaxel)
CRPC patients suggests these agents
are superior at inhibiting the AR signaling
axis and, importantly, confirms that further
hormonal manipulations in CRPC are an
effective therapeutic strategy. Although
‘‘androgen-independent clones’’ may ulti-
mately give rise to an ‘‘androgen-indepen-
dent tumor,’’ these clinical data indicate
that therapeutic attempts to completely
ablate processes that associate with
steroid receptor signaling will give
patients real clinical benefit. These obser-
vations have led to a very substantial
investment in the development of novel
drugs that target the AR signaling axis,
and both of these agents are now under-
going evaluation in large, randomized,
double-blind, phase III studies designed
to identify a survival benefit and obtain
regulatory approval to treat CRPC.
Abiraterone acetate is well tolerated,
and no dose-limiting toxicities were
observed at the highest dose evaluated
(2000 mg daily continuously). The main
toxicities reported were related to
a syndrome of secondary mineralocorti-
coid excess that was reversed by either
a mineralocorticoid antagonist or sup-
pression of raised ACTH with low-dose
daily exogenous glucocorticoids (Attard
et al., 2008b). MDV-3100 is also well toler-
ated, although full publication of the
phase I results is currently awaited (Tran
et al., 2009). The long-term toxicities
associated with inhibition of the AR in
men treated for long periods of time with
these agents remain unstudied.
Reports to date suggest resistance to
these agents commonly develops within
12–36 months and is nearly invariably
characterized by a rising PSA. This
suggests that although CRPC resistant
to these agents may contain androgen-
independent clones, a significant portion
of the tumor remains ‘‘addicted’’ to acti-
vation of the AR or its downstream
targets. We hypothesize that strategiesCancer Cell 16,that improve on the efficacy of the current
phase III combination of these drugs with
castration will improve outcome. These
could include (1) the sequential or combi-
natorial use of these agents; (2) the contin-
uation of treatment beyond objective
progression and in combination with sub-
sequent treatments in order to achieve
long-term supercastration or androgen
blockade; (3) the development of novel
drugs that ablate ligand-binding domain
(LBD)-independent AR signaling with the
aim of reversing resistance to abiraterone
or MDV-3100; or (4) the direct targeting of
rearranged ETS genes or their down-
stream effectors which could abrogate
the need for therapeutic castration. The
observation or absence of responses to
one drug after progression on the other
will inform on the best strategy.
Androgens in CRPC
Up to 20% of serum androgens in the
noncastrate male are nongonadal in
origin: serum androstenedione and dehy-
droepiadrostenedione (DHEA) levels in
castrate men are similar to levels in
noncastrate men and could activate
the AR and other steroid receptors. Simi-
larly, the recent use of super-sensitive
LC-MS/MS assays has confirmed detect-
able serum testosterone levels in the
majority of castrate CRPC patients (Attard
et al., 2008b). Intraprostatic testosterone
levels fall immediately after castration in
cancer patients but rise to precastration
levels after development of castration
resistance (Mohler et al., 2004). This could
either be secondary to upregulation of
enzymes involved in the conversion of
adrenal androgens to testosterone that
has been reported in CRPC (Stanbrough
et al., 2006) or to intratumoral synthesis
of androgens from pregnenolone and
other precursors. De novo synthesis of
androgens has been demonstrated in
androgen-dependent xenograft tumor
models when exposed to androgen-
deprived conditions (Locke et al., 2008),
and several enzymes, including CYP17,
involved in steroid biosynthesis are highly
expressed in CRPC (Montgomery et al.,
2008). These data introduce the possi-
bility that inhibition of intratumoral
CYP17 expression and intracrine tumor
steroid synthesis could account for the
significant antitumor activity of abirater-
one. This remains to be confirmed clini-
cally in prospective clinical trials and, inDecember 8, 2009 ª2009 Elsevier Inc. 459
Cancer Cell
Perspectivefact, suppression of serum steroids,
which mostly originate from the adrenal
glands, could be sufficient to explain the
tumor responses observed with abirater-
one acetate (Attard et al., 2008b). Also,
pretreatment serum androgen and estra-
diol levels are associated with tumor
responses to CYP17 inhibition with either
abiraterone acetate or the nonspecific
CYP17 inhibitor ketoconazole (Attard
et al., 2009a; Ryan et al., 2007), further
supporting a role for serum hormones in
driving CRPC. In contrast to treatment
with ketoconazole, no rise in serum
hormones at disease progression on abir-
aterone has been reported to date (Attard
et al., 2008b; Small et al., 2004). It is
however possible that more sensitive
tests could detect very low levels of serum
androgens that could support the growth
of CRPC cells in patients treated with
abiraterone. Also, although no evidence
to support this has been reported, CRPC
could potentially become resistant to
abiraterone following synthesis of andro-
gens via CYP17-independent pathways




AR gene amplification is reported in one-
third of CRPC tumors. Since this is signif-
icantly less common in untreated tumors,
it has been proposed that gene amplifica-
tion is the result of selective pressure
exerted by androgen deprivation (Buben-
dorf et al., 1999; Visakorpi et al., 1995).
Similarly, the prevalence of AR mutations
in tumor tissue increases with exposure to
castration, antiandrogens, and other lines
of hormone treatment (Buchanan et al.,
2001; Taplin et al., 2003).
The vast majority of these AR gene
mutations collocate to the signature
sequence and Activation-Function-2
(AF-2), two discrete regions of the
ligand-binding domain LBD, and result in
loss of ligand specificity of the AR
(Buchanan et al., 2001). For example,
the human prostate cancer cell line
LNCaP has an AR point mutation (Thr-
Ala877) that has been detected in up
to 15% of clinical samples and results
in inappropriate activation by several
ligands, including progestins, estrogens,
adrenal androgens, steroidal compounds
such as the diuretic spironolactone, and
antiandrogens (Grigoryev et al., 2000;460 Cancer Cell 16, December 8, 2009 ª200Luthy et al., 1988; Taplin et al., 2003;
Veldscholte et al., 1992). Also, mutations
involving cofactor binding sites can lead
to enhanced coactivator binding and
stabilization of the AR, or a loss of interac-
tion with corepressors (Brooke and
Bevan, 2009). An increase in AR mRNA
expression is sufficient in vitro to convert
the action of bicalutamide from an overall
AR antagonist to an agonist (Chen et al.,
2004). These data provide a molecular
explanation for the phenotypic phenom-
enon whereby currently available antian-
drogens become agonistic in at least one
in five patients (Small et al., 2004). Simi-
larly, ligands other than testosterone or
dihyrdotestosterone could result in potent
activation of AR signaling (Culig et al.,
1993; Fenton et al., 1997; Zhao et al.,
2000). MDV-3100 binds to the AR LBD
but has shown no AR agonistic activity in
preclinical models (Tran et al., 2009).
Further support for the hypothesis that
a promiscuous AR becomes a ‘‘driving’’
oncogene is provided by reports of PSA
responses in 25% of patients pro-
gressing on abiraterone acetate alone
when low-dose corticosteroids were
added, despite prior documented tumor
progression on the same corticosteroid
dose and regimen (Attard et al., 2008b,
2009a). Although alternative are possible,
these data suggest that AR signaling was
initially abrogated by suppression of an-
drogen LBD and estrogens downstream
of CYP17 and subsequently reactivated
by a rise in the level of upstream steroids
driven by high levels of adrenocorticotro-
phic hormone that are suppressed by
exogenous corticosteroids. Overall, these
observations support the current clinical
development of abiraterone acetate in
combination with prednisone.
Genetic aberrations of theAR, including
high copy number amplification of the AR,
and changes in the AR coactivator/core-
pressor balance could also result in
constitutive activation. Recent reports
suggest that naturally occurring AR splice
variants lacking the LBD but retaining the
Activation-Function-1 (AF-1) region in the
N-terminal domain, which in isolation is
a potent activator of AR transcriptional
activity and could induce canonical
androgen-responsive gene expression in
the absence of androgens, could be
selected for by androgen deprivation
(Dehm et al., 2008). This could potentially
lead to resistance to drugs that inhibit9 Elsevier Inc.steroid synthesis and antiandrogens that
bind the AR LBD, including MDV-3100.
Alternative strategies for targeting the
AR signaling axis that are not dependent
on the AR LBD are therefore required.
One strategy that is undergoing clinical
evaluation is the targeting of AR post-
translational maturation by blocking
chaperone proteins. Preclinical reports
indicate that aberrant (mutated) oncopro-
teins may be more dependent on chap-
erone proteins for maintaining stability
and avoiding ubiquitination (Banerji et al.,
2008), suggesting increased sensitivity
of aberrant AR in multidrug resistant
disease. AR is maintained in the cyto-
plasm in a complex that includes the
heat shock protein HSP90; following
ligand binding, HSP27 displaces HSP90
from this complex and chaperones AR
into the nucleus (Zoubeidi et al., 2007). It
is unclear whether AR splice variants are
also dependent on heat shock proteins
and other components of the AR tran-
scription complex. Nonetheless, both
HSP90 and HSP27 are potential thera-
peutic targets in prostate cancer. HSP27
is an ATP-independent chaperone that is
currently being targeted therapeutically
using the antisense nucleotide OGX-427
(Zoubeidi et al., 2007). Several specific
HSP90 inhibitors are undergoing clinical
evaluation, although better blockade of
HSP90 could be achieved with alternative
strategies: for example, concurrent inhibi-
tion of HSP70 and HSP72 (Powers et al.,
2008). We have reported suppression of
HSP90 in clinical studies of the histone
deacetylase inhibitor (HDACi) LAQ824
(de Bono et al., 2008) but very limited anti-
tumor activity in CRPC with the HDACi
depsipeptide (Molife et al., 2009). Recent
preclinical data support the further clini-
cal development for CRPC of HDACi
that have improved tolerability and supe-
rior pharmacological properties (Welsbie
et al., 2009). These strategies could
achieve complete ablation of the AR and
improve significantly on current thera-
peutic strategies, especially if unliganded
AR and LBD-lacking AR variants serve as
cytoplasmic or cell membrane signaling
proteins as do other steroid receptors,
including the ER (Pedram et al., 2006), or
regulate tumorigenesis via distinct mech-
anisms, including through upregulation of
M-phase cell-cycle genes (Wang et al.,
2009). Also, therapeutic targeting of the
AF-2 region in the N-terminal domain
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but could potentially achieve complete
abrogation of AR transcriptional activity.
There is strong preclinical evidence to
support crosstalk between receptor tyro-
sine kinases: for example, members of
the family of epidermal growth factor
(EGF) receptors and their downstream
targets and steroid receptor networks re-
sulting in activation of steroid-regulated
transcription in the absence of ligand
(Craft et al., 1999; Culig et al., 1994). For
example, HER2 kinase activity results in
prostate tumor growth in ‘‘androgen-
independent’’ preclinical models. These
data led to the clinical evaluation of thera-
peutics targeting EGFR or HER2 in CRPC
that, however, failed to demonstrate any
clinical benefit, despite proven antitumor
activity with the same dose and regimen
in other tumor types (de Bono et al.,
2007; Pezaro et al., 2009; Ziada et al.,
2004). Similarly, other networks such as
the Wnt/b-catenin pathway that have
been reported to cause androgen-inde-
pendence through inappropriate activa-
tion of the AR (Verras et al., 2004) are
undergoing early clinical evaluation. As
it becomes increasingly evident that
the AR and other steroid receptors
remain activated in CRPC, the role of
crosstalk should be considered inade-
quately explored in the clinic by single-
agent testing of these agents—future
trials must evaluate therapeutics targeting
crosstalk pathways in patients in whom
AR and other steroid receptor signaling
has been truly abrogated.
Estrogen and Other Steroid
Receptors
Evidence is emerging that steroid recep-
tors other than the AR regulate prostate
cancer cell proliferation and survival. In
the prostate cancer cell line NCI-H660,
transcription of TMPRSS2:ERG is modu-
lated by functional ERa and ERb in a yin-
yang fashion (Setlur et al., 2008). Compu-
tational analysis of expression array data
suggests a central role for ER-related
pathways in prostate cancer. Further-
more, increased expression of ERa and
decreased expression of ERb has been
associated with prostate cancer progres-
sion (Ellem and Risbridger, 2007). Estro-
gens are suppressed by abiraterone,
and this could account for some of its
antitumor activity. Similarly, response
elements upstream of TMPRSS2 can beactivated by other steroid receptors,
including vitamin D (Attard et al., 2008a).
The role of these other steroid receptors
and their variants in CRPC appear
increasingly relevant. Although phase II
clinical studies of the ER antagonist,
tamoxifen, and aromatase inhibitors have
reported no activity in CRPC, a role for
these drugs may be found in combination
with agents that target the AR. One impor-
tant clinical trial could be an evaluation
of whether aromatase inhibitors such as
letrozole can reverse resistance to novel
antiandrogens such as MDV3100.
Future Directions
We recently reported highly heteroge-
neous loss of PTEN and gain of AR in
CTC, suggesting the existence of multiple
different malignant clones that could have
developed different mechanisms of resis-
tance to castration in the same CRPC
patient (Attard et al., 2009c). The intrapa-
tient heterogeneity of PTEN loss and AR
gain in CRPC was, however, associated
with highly homogeneous ERG gene
rearrangement status (Attard et al.,
2009c). This supports our hypothesis that
although multiple different mechanisms
for inducing overexpression of ERG may
exist in the same patient, an ERG-rear-
ranged tumor does not change its under-
lying ERG gene status. Similarly, other
hormone-regulated oncogenic mecha-
nisms could persist throughout all stages
of the disease. This introduces the
possibility of overcoming resistance to
hormone treatments by therapeutically
targeting ETS gene fusions or their down-
stream targets. Importantly, this could
achieve therapeutic benefit but avoid the
inevitable toxicities of androgen depriva-
tion. We have reported an association
between the presence of an ERG gene
rearrangement and magnitude of PSA
decline and falls in CTC counts with abira-
terone acetate (Attard et al., 2009c); we
postulate that further molecular character-
ization of this disease using analytically
validated, predictive biomarkers in a
combination of tumor tissue and CTC
could allow the molecular stratification of
patients to ensure they are enrolled to
trials of appropriately matched targeted
drugs, preferably in drug combinations to
simultaneously target molecularly hetero-
geneous clones. Ongoing phase III studies
of abiraterone acetate and MDV-3100 are
also evaluating whether a change in CTCCancer Cell 16,count with treatment is a robust surrogate
of survival, with the aim of validating a
decline in CTC count as an intermediate
endpoint for accelerating drug approval
in future regulatory phase III trials.
In conclusion, clinical studies with im-
proved inhibitors of AR signaling indicate
that a significant proportion of CRPC finds
AR signaling a ‘‘hard habit to break.’’
Further studies must now confirm that this
disease commonly remains truly addicted
to nuclear steroid receptor signaling. Key
research questions for the identification of
future therapeutic targets include:
d Is the oncogenic mechanism un-
derlying steroid receptor activation
entirely attributable to overexpres-
sion of hormone-regulated gene
fusions?
d How does steroid receptor activa-
tion occur in patients whose cancers
are resistant to drugs such as abira-
terone and MDV-3100?
d Can prostate cancer lose its addic-
tion to steroid receptor activation
and yet remain driven by the same
downstream targets?
Answers to these questions will inform
the future development of therapeutics
for CRPC. Efforts to develop strategies
to overcome resistance to abiraterone
and MDV-3100 must commence now, in
advance of the conclusion of regulatory
studies evaluating their use in the treat-
ment of CRPC. Moreover, future investi-
gations should also focus on developing
predictive biomarkers that subdivide
CRPC into distinct molecular entities to
allow the conduct of trials and clinical
use of targeted therapies in an enriched
sensitive population. This is vital to accel-
erating anticancer drug approval and
fixing the broken drug development pipe-
line for this disease.
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